AstraZeneca’s Farxiga Flies Across $1bn Barrier
Stellar Sales Of SGLT2 Inhibitor
First-quarter sales jumped by 56% to $11.39bn at AstraZeneca and while its COVID-19 products brought in $1.6bn, it was the performance of the diabetes, heart failure and chronic kidney disease drug Farxiga that impressed most.
